Andrew Komjathy, Chief Commercial Officer at Astria Therapeutics, Inc. (ATXS), bought 100 shares at $6.70 ($670) on 2021-11-19, disclosed to the SEC on 2021-11-23.
Open-market purchase of $670 ATXS by Chief Commercial Officer. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Nothing distinguishes this filing.